Back to Research Hub
Aurinia Pharmaceuticals Inc.
AUPH
$15.78+0.12 (+0.77%)
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
StreetsValue research for Aurinia Pharmaceuticals Inc. (AUPH)
Members get the full report for Aurinia Pharmaceuticals Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.